在监测、流行病学和最终结果注册数据库中,对有利风险前列腺癌接受保守管理或根治性前列腺切除术的患者使用Decipher前列腺活检检测
基于监测、流行病学和最终结果注册数据库2016至2018年87 140例1至2级前列腺癌患者,其中2576例接受Decipher 22基因基因组分类器活检检测。检测与保守管理几率增加相关(OR 2.1,95%CI 1.9-2.4,p<0.001),较高基因组评分与根治性前列腺切除术后不良病理结局相关。
要点
- 接受基因组分类器检测的患者更可能接受保守管理(OR 2.1,95%CI 1.9-2.4,p<0.001)。
- 活检基因组分类器风险分布为低危45%、中危30%、高危25%。
- 较高基因组评分与病理升级、分期升级及不良病理均显著相关。
核心结论
- 接受基因组分类器检测的男性更可能接受保守管理。
- 活检时基因组分类器检测在大型人群注册数据库中可预测不良病理结局。
研究设计与样本
- 回顾性注册数据库研究,链接监测、流行病学和最终结果注册数据与基因组分类器检测结果。
- 共纳入2016至2018年诊断的1至2级前列腺癌患者87 140例,其中2576例接受检测、84 564例未检测。
主要发现
- 检测组活检2级比例51% vs 未检测组46%(p<0.001),前列腺特异性抗原6.1 vs 6.3(p=0.016)。
- 2016至2018年保守管理在检测组从37%增至39%,在未检测组从22%增至24%。
- 基因组分类器检测与保守管理几率增加显著相关(OR 2.1,95%CI 1.9-2.4,p<0.001)。
- 调整分析中,较高基因组评分(每0.1增量)(OR 1.24,95%CI 1.17-1.31,p<0.001)和阳性针芯百分比(OR 1.07,95%CI 1.02-1.12,p=0.009)与接受根治性前列腺切除术显著相关。
- 较高基因组评分与病理升级(OR 1.29,95%CI 1.12-1.49,p<0.001)、分期升级(OR 1.31,95%CI 1.05-1.62,p=0.020)及不良病理(OR 1.27,95%CI 1.12-1.45,p<0.001)均显著相关。
关键数值与推荐
- 活检基因组分类器风险分布:低危45%、中危30%、高危25%。
临床怎么用
- 作者指出,前列腺活检时使用基因组检测可改善风险分层,可能比单独使用肿瘤体积更好地指导治疗决策。
局限性
- 局限性包括回顾性研究设计相关的观察性偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The extent of prostate cancer found on biopsy, as well as prostate cancer grade and genomic tests, can affect clinical decision-making. The impact of these factors on the initial management approach and subsequent patient outcomes for men with favorable-grade prostate cancer has not yet been determined on a population level. Our objective was to explore the association of Decipher 22-gene genomic classifier (GC) biopsy testing on the initial use of conservative management versus radical prostatectomy (RP) and to determine the independent effect of GC scores on RP pathologic outcomes. METHODS: A total of 87 140 patients diagnosed with grade group 1 and 2 prostate cancer between 2016 and 2018 from the Surveillance, Epidemiology, and End Results registry data were linked to GC testing results (2576 tested and 84 564 untested with a GC). The primary endpoints of interest were receipt of conservative management or RP, pathologic upgrading (pathologic grade group 3-5), upstaging (pathologic ≥T3b), and adverse pathologic features (pathologic upgrading, upstaging, or lymph node invasion). Multivariable logistic regressions quantified the association of variables with outcomes of interest. KEY FINDINGS AND LIMITATIONS: GC tested patients were more likely to have grade group 2 on biopsy (51% vs 46%, p < 0.001) and lower prostate-specific antigen (6.1 vs 6.3, p = 0.016). Conservative management increased from 37% to 39% and from 22% to 24% during 2016-2018 for the GC tested and untested populations, respectively. GC testing was significantly associated with increased odds of conservative management (odds ratio [OR] 2.1, 95% confidence interval [CI] 1.9-2.4, p < 0.001). The distribution of biopsy GC risk was as follows: 45% low risk, 30% intermediate risk, and 25% high risk. In adjusted analyses, higher GC (per 0.1 increment) scores (OR 1.24, 95% CI 1.17-1.31, p < 0.001) and percent positive cores (1.07, 95% CI 1.02-1.12, p = 0.009) were significantly associated with the receipt of RP. A higher GC score was significantly associated with all adverse outcomes (pathologic upgrading [OR 1.29, 95% CI 1.12-1.49, p < 0.001], upstaging [OR 1.31, 95% CI 1.05-1.62, p = 0.020], and adverse pathology [OR 1.27, 95% CI 1.12-1.45, p < 0.001]). Limitations include observational biases associated with the retrospective study design. CONCLUSIONS AND CLINICAL IMPLICATIONS: Men who underwent GC testing were more likely to undergo conservative management. GC testing at biopsy is prognostic of adverse pathologic outcomes in a large population-based registry. PATIENT SUMMARY: In this population analysis of men with favorable-risk prostate cancer, those who underwent genomic testing at biopsy were more likely to undergo conservative management. Of men who initially underwent radical prostatectomy, higher genomic risk but not tumor volume was associated with adverse pathologic outcomes. The use of genomic testing at prostate biopsy improves risk stratification and may better inform treatment decisions than the use of tumor volume alone.
引用
- Zhu A, Proudfoot JA, Davicioni E, et al. Use of Decipher Prostate Biopsy Test in Patients with Favorable-risk Disease Undergoing Conservative Management or Radical Prostatectomy in the Surveillance, Epidemiology, and End Results Registry. Eur Urol Oncol. 2024. PMID: 38972832. doi:10.1016/j.euo.2024.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。